152 related articles for article (PubMed ID: 19237629)
1. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
Dong X; Jiao L; Li Y; Evans DB; Wang H; Hess KR; Abbruzzese JL; Li D
J Clin Oncol; 2009 Apr; 27(10):1592-9. PubMed ID: 19237629
[TBL] [Abstract][Full Text] [Related]
2. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.
Dong X; Li Y; Hess KR; Abbruzzese JL; Li D
Oncologist; 2011; 16(1):61-70. PubMed ID: 21212431
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Chen J; Li D; Killary AM; Sen S; Amos CI; Evans DB; Abbruzzese JL; Frazier ML
Ann Surg Oncol; 2009 Feb; 16(2):431-9. PubMed ID: 19020940
[TBL] [Abstract][Full Text] [Related]
4. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.
Tanaka M; Okazaki T; Suzuki H; Abbruzzese JL; Li D
Cancer; 2011 Feb; 117(4):744-51. PubMed ID: 20922799
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
Li D; Frazier M; Evans DB; Hess KR; Crane CH; Jiao L; Abbruzzese JL
J Clin Oncol; 2006 Apr; 24(11):1720-8. PubMed ID: 16520463
[TBL] [Abstract][Full Text] [Related]
6. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.
Okazaki T; Jiao L; Chang P; Evans DB; Abbruzzese JL; Li D
Clin Cancer Res; 2008 Apr; 14(7):2042-8. PubMed ID: 18381943
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.
Dong X; Javle M; Hess KR; Shroff R; Abbruzzese JL; Li D
Gastroenterology; 2010 Aug; 139(2):464-73, 473.e1-3. PubMed ID: 20416304
[TBL] [Abstract][Full Text] [Related]
8. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
[No Abstract] [Full Text] [Related]
9. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Okazaki T; Javle M; Tanaka M; Abbruzzese JL; Li D
Clin Cancer Res; 2010 Jan; 16(1):320-9. PubMed ID: 20028759
[TBL] [Abstract][Full Text] [Related]
10. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Shinozuka K; Tang H; Jones RB; Li D; Nieto Y
Biol Blood Marrow Transplant; 2016 May; 22(5):843-9. PubMed ID: 26743341
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer.
Dong X; Li Y; Chang P; Hess KR; Abbruzzese JL; Li D
Mol Carcinog; 2012 Jun; 51(6):491-9. PubMed ID: 21681824
[TBL] [Abstract][Full Text] [Related]
13. Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy.
Yang J; Huang Y; Feng Y; Li H; Feng T; Chen J; Yin L; Wang W; Wang S; Liu Y; Song Y; Li Y; Jin J; Tan W; Lin D
Cancer Res Treat; 2019 Jul; 51(3):1198-1206. PubMed ID: 30590005
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
15. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
17. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Li D; Liu H; Jiao L; Chang DZ; Beinart G; Wolff RA; Evans DB; Hassan MM; Abbruzzese JL
Cancer Res; 2006 Mar; 66(6):3323-30. PubMed ID: 16540687
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
19. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]